These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 39358546)

  • 1. Immunogenic cell death signatures from on-treatment tumor specimens predict immune checkpoint therapy response in metastatic melanoma.
    Zeng H; Jiang Q; Zhang R; Zhuang Z; Wu J; Li Y; Fang Y
    Sci Rep; 2024 Oct; 14(1):22872. PubMed ID: 39358546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma Patients.
    Mallardo D; Fordellone M; White A; Vowinckel J; Bailey M; Sparano F; Sorrentino A; Mallardo M; Facchini BA; De Filippi R; Ferrara G; Vanella V; Beeler K; Chiodini P; Cesano A; Warren S; Ascierto PA
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional Gene Expression Signatures from On-Treatment Tumor Specimens Predict Anti-PD1 Blockade Response in Metastatic Melanoma.
    Chen S; Zhang L; Lin H; Liang Y; Wang Y
    Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response.
    Lim SY; da Silva IP; Adegoke NA; Lo SN; Menzies AM; Carlino MS; Scolyer RA; Long GV; Lee JH; Rizos H
    Mol Cancer; 2024 Oct; 23(1):228. PubMed ID: 39394099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
    Ye W; Olsson-Brown A; Watson RA; Cheung VTF; Morgan RD; Nassiri I; Cooper R; Taylor CA; Akbani U; Brain O; Matin RN; Coupe N; Middleton MR; Coles M; Sacco JJ; Payne MJ; Fairfax BP
    Br J Cancer; 2021 May; 124(10):1661-1669. PubMed ID: 33723392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade.
    Onieva JL; Xiao Q; Berciano-Guerrero MÁ; Laborda-Illanes A; de Andrea C; Chaves P; Piñeiro P; Garrido-Aranda A; Gallego E; Sojo B; Gálvez L; Chica-Parrado R; Prieto D; Pérez-Ruiz E; Farngren A; Lozano MJ; Álvarez M; Jiménez P; Sánchez-Muñoz A; Oliver J; Cobo M; Alba E; Barragán I
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma.
    Coleman S; Xie M; Tarhini AA; Tan AC
    Mol Carcinog; 2023 Jan; 62(1):77-89. PubMed ID: 35781709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma.
    Du K; Wei S; Wei Z; Frederick DT; Miao B; Moll T; Tian T; Sugarman E; Gabrilovich DI; Sullivan RJ; Liu L; Flaherty KT; Boland GM; Herlyn M; Zhang G
    Nat Commun; 2021 Oct; 12(1):6023. PubMed ID: 34654806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
    Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
    Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
    Auslander N; Zhang G; Lee JS; Frederick DT; Miao B; Moll T; Tian T; Wei Z; Madan S; Sullivan RJ; Boland G; Flaherty K; Herlyn M; Ruppin E
    Nat Med; 2018 Oct; 24(10):1545-1549. PubMed ID: 30127394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
    Dravillas CE; Coleman SS; Hoyd R; Caryotakis G; Denko L; Chan CHF; Churchman ML; Denko N; Dodd RD; Eljilany I; Hardikar S; Husain M; Ikeguchi AP; Jin N; Ma Q; McCarter MD; Osman AEG; Robinson LA; Singer EA; Tinoco G; Ulrich CM; Zakharia Y; Spakowicz D; Tarhini AA; Tan AC;
    Cancer Res Commun; 2024 Aug; 4(8):1978-1990. PubMed ID: 39015091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8
    Chen X; Xu R; He D; Zhang Y; Chen H; Zhu Y; Cheng Y; Liu R; Zhu R; Gong L; Xiao M; Wang Z; Deng L; Cao K
    Oncogene; 2021 Oct; 40(43):6223-6234. PubMed ID: 34552192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
    Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
    Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
    Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An immune risk score with potential implications in prognosis and immunotherapy of metastatic melanoma.
    Sheng Y; Tong L; Geyu L
    Int Immunopharmacol; 2020 Nov; 88():106921. PubMed ID: 32871477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel prognostic biomarker LCP2 correlates with metastatic melanoma-infiltrating CD8
    Wang Z; Peng M
    Sci Rep; 2021 Apr; 11(1):9164. PubMed ID: 33911146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic model incorporating immune checkpoint genes to predict the immunotherapy efficacy for lung adenocarcinoma: a cohort study integrating machine learning algorithms.
    Yang XL; Zeng Z; Wang C; Wang GY; Zhang FQ
    Immunol Res; 2024 Aug; 72(4):851-863. PubMed ID: 38755433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimentally validated oxidative stress -associated prognostic signatures describe the immune landscape and predict the drug response and prognosis of SKCM.
    Rong D; Su Y; Jia D; Zeng Z; Yang Y; Wei D; Lu H; Cao Y
    Front Immunol; 2024; 15():1387316. PubMed ID: 38660305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma.
    Mao R; Yang F; Zhang T; Li J
    Front Immunol; 2021; 12():756282. PubMed ID: 35003069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.